XGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.850

Open

4.390

VWAP

4.63

Vol

286.10K

Mkt Cap

115.97M

Low

4.230

Amount

1.32M

EV/EBITDA(TTM)

Total Shares

24.16M

110.57M

EV/OCF(TTM)

P/S(TTM)

1.47

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Events Timeline

(ET)

2026-05-11

08:20:00

Exagen Q1 Revenue $17.31M Beats Expectations

2026-05-11

08:20:00

Company Expects Full-Year 2026 Revenue of $70M to $73M

News

8.5

06-01Newsfilter

Exagen Publishes Study on AVISE Lupus Algorithm's Diagnostic Superiority

9.5

05-12Yahoo Finance

Exagen Reports 12% Year-over-Year Revenue Growth in Q1

9.5

05-12seekingalpha

Exagen Reports Record Q1 2026 Revenue of $17.3 Million

9.5

04-27Newsfilter

Exagen to Release Q1 2026 Financial Results

9.5

03-10seekingalpha

Exagen Inc. Reports Record Q4 2025 Earnings and Growth Outlook

9.5

03-10seekingalpha

Exagen Reports Q4 Earnings Miss Despite Revenue Growth

7 Analyst Rating

Wall Street analysts forecast XGN stock price to rise

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

15.20

High

18.00

Current: 0.000

Low

13.00

Averages

15.20

High

18.00

Roth Capital

Max Masucci

initiated

AI Analysis

2026-06-24

Reason

Roth Capital

Max Masucci

Price Target

AI Analysis

2026-06-24

initiated

Reason

Roth Capital analyst Max Masucci initiated coverage of Exagen with a Buy rating and $8 price target. Exagen's autoimmune testing portfolio, headlined by its AVISE CTD test, faces no head-to-head competition and outperforms conventional biomarker testing, the analyst tells investors in a research note. The firm added that over 1.2M tests have been completed since launch, and sees the stock as an "execution story" with runway for market penetration beyond roughly 6%-7% today.

Roth Capital

Buy

initiated

2026-06-24

Reason

Roth Capital

Price Target

2026-06-24

initiated

Buy

Reason

Roth Capital initiated coverage of Exagen with a Buy rating and $8 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Exagen Inc (XGN.O) is 0.00, compared to its 5-year average forward P/E of -4.94. For a more detailed relative valuation and DCF analysis to assess Exagen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.94

Current PE

0.00

Overvalued PE

0.36

Undervalued PE

-10.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.91

Current EV/EBITDA

-8.23

Overvalued EV/EBITDA

14.86

Undervalued EV/EBITDA

-42.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.65

Current PS

1.34

Overvalued PS

2.78

Undervalued PS

0.52

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

low float medical tech stock

Intellectia · 68 candidates

Market Cap: 50.00M - 5.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchRegion: USPrice: $1.00 - $50.00Beta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000Floating Shares: <= 20,000,000

Ticker

Name

Market Cap$

XLO

Xilio Therapeutics Inc

50.19M

LPCN

Lipocine Inc

54.02M

LFVN

LifeVantage Corp

54.88M

CLNN

Clene Inc

63.49M

Outset Medical Inc

64.46M

ACET

Adicet Bio Inc

64.58M

low float high volume

Intellectia · 49 candidates

Region: USVolume: >= 500,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

FAT

FAT Brands Inc

5.25M

APRE

Aprea Therapeutics Inc

5.57M

FATBB

FAT Brands Inc

27.81M

YCBD

cbdMD Inc

10.92M

LXEH

Lixiang Education Holding Co Ltd

6.50M

KXIN

Kaixin Holdings

29.77M

Whales Holding XGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Exagen Inc (XGN) stock price today?

The current price of XGN is 4.8 USD — it has increased 9.09

What is Exagen Inc (XGN)'s business?

What is the price predicton of XGN Stock?

Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is15.20 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.